製備超順磁性水膠複合微粒及其在藥物傳輸系統上之應用

Preparation of Superparamagnetic Nanoparticle-Hydrogel Composites and their Application on Drug Delivery System

曾志中(Chih-Chung Tseng)

指導教授 ： 陳家俊

國立臺灣師範大學/理學院/化學系/碩士(2006年)

摘要

近幾年來，奈米粒子-高分子複合材料由於分析和合成技術的進步，受到廣泛的研究及討論。超順磁性的FePt奈米粒子經由Cysteamine表面修飾轉為水相後，藉由 TEM、XRD和SQUID儀器鑑定其結構及性質沒有改變，界面電位顯示水相FePt奈米粒子帶正電，利用此表面性質以化學方法和溫感型水膠結合形成奈米粒子-高分子複合微粒，經TEM、XRD證實此複合微粒具有水膠及FePt奈米粒子，亦觀察到此複合微粒擁有孔洞可用來攜帶藥物。以DLS在溫度變化下觀察到複合微粒反覆以收縮或膨潤應答，表示此複合微粒仍保有水膠之性質。在藥物傳輸系統上之應用，我們設計了完整的流程探求FePt奈米粒子-水膠複合微粒乘載和釋放藥物的能力，並且利用溫度的差異控制藥物釋放的程度和效率。因此我們認為這種奈米粒子-高分子複合微粒在磁熱治療上極具潛力。

關鍵字

鐵鉑合金 ； 水膠 ； 複合物 ； 藥物傳輸系統

並列摘要

For the advances of analytic and synthetic technology recently, the nanoparticle-polymer composites are extensively researched and discussed. The properties and structures of the superparamagnetic FePt nanoparticles remain and are proven by TEM, XRD and SQUID after modified with Cysteamine and turning to be hydrophilic. Their zeta potential approves that they are positively charged. The FePt nanoparticles combining with temperature-sensitive hydrogels become nanoparticle-hydrogel composites and the composites indeed have FePt and hydrogel by TEM and XRD observations. The composites as well as the hydrogel swell or shrink by DLS detection when temperature changes and this effect reveals that the composites retain the properties of the hydrogel. We have good avenues to measure the ability of the composites to load and release drugs under the subject of drug delivery system. We also control the quantity and efficiency of drug releasing by tuning temperature. We think that the composites promise well on the field of magnetic hyperthermia.

並列關鍵字

FePt ； Hydrogel ； Composite ； Drug Delivery System

參考文獻

4.Soppimath, K. S.; Aminabhavi T. M.; Dave A. M.; Kumbar S. G.; Rudzinski W. E. Drug Dev. Ind. Pharm. 2002, 28,957-974.

30.Neuberger, T.; Sch?pf, B.; Hofmann, H.; Hofmann, M.;

19.Liu, T. Y.; Hu, S. H.; Liu, K. H.; Liu, D. M.; Chen, S. Y. J. Magn. Magn. Mater. 2006, 304, 397-399.

5.Bromberg, L. E.; Ron E. S. Adv. Drug Deliv. Rev. 1998, 31, 197-221.

6.Sershen, S.; West J. Adv. Drug Deliv. Rev. 2002, 54, 1225-1235.